Royce & Associates LP Buys 105,632 Shares of Elanco Animal Health Incorporated $ELAN

Royce & Associates LP raised its stake in Elanco Animal Health Incorporated (NYSE:ELAN) by 21.3% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 602,564 shares of the company’s stock after acquiring an additional 105,632 shares during the period. Royce & Associates LP’s holdings in Elanco Animal Health were worth $12,136,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the stock. Goldman Sachs Group Inc. boosted its holdings in shares of Elanco Animal Health by 104.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company’s stock valued at $50,268,000 after purchasing an additional 2,445,872 shares during the last quarter. Bowen Hanes & Co. Inc. purchased a new stake in shares of Elanco Animal Health in the third quarter worth about $47,626,000. Jupiter Asset Management Ltd. lifted its position in shares of Elanco Animal Health by 98.8% in the third quarter. Jupiter Asset Management Ltd. now owns 3,716,849 shares of the company’s stock worth $74,857,000 after buying an additional 1,846,907 shares in the last quarter. Primecap Management Co. CA boosted its stake in Elanco Animal Health by 3.1% during the second quarter. Primecap Management Co. CA now owns 51,766,814 shares of the company’s stock valued at $739,230,000 after buying an additional 1,543,279 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its holdings in Elanco Animal Health by 266.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,918,336 shares of the company’s stock valued at $38,635,000 after buying an additional 1,394,839 shares in the last quarter. Hedge funds and other institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Stock Down 1.3%

Shares of NYSE ELAN opened at $26.05 on Tuesday. Elanco Animal Health Incorporated has a 1 year low of $8.02 and a 1 year high of $27.72. The firm has a 50-day simple moving average of $24.31 and a two-hundred day simple moving average of $21.87. The company has a market cap of $12.95 billion, a P/E ratio of -54.27, a PEG ratio of 3.38 and a beta of 1.83. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.17 and a quick ratio of 1.08.

Elanco Animal Health (NYSE:ELAN) last released its earnings results on Tuesday, February 24th. The company reported $0.13 EPS for the quarter, beating analysts’ consensus estimates of $0.11 by $0.02. Elanco Animal Health had a positive return on equity of 7.16% and a negative net margin of 4.92%.The firm had revenue of $1.14 billion for the quarter, compared to analysts’ expectations of $1.09 billion. During the same quarter in the prior year, the firm posted $0.14 earnings per share. The company’s quarterly revenue was up 12.2% on a year-over-year basis. Elanco Animal Health has set its Q1 2026 guidance at 0.330-0.36 EPS and its FY 2026 guidance at 1.000-1.060 EPS. Research analysts anticipate that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have issued reports on ELAN. Argus raised Elanco Animal Health from a “hold” rating to a “buy” rating and set a $25.00 price objective on the stock in a research note on Wednesday, November 19th. Leerink Partners raised their target price on shares of Elanco Animal Health from $26.00 to $30.00 and gave the company an “outperform” rating in a report on Tuesday, February 24th. KeyCorp boosted their price target on shares of Elanco Animal Health from $27.00 to $29.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 25th. JPMorgan Chase & Co. upped their price target on shares of Elanco Animal Health from $24.00 to $28.00 and gave the company an “overweight” rating in a research note on Thursday, February 19th. Finally, Wall Street Zen upgraded shares of Elanco Animal Health from a “buy” rating to a “strong-buy” rating in a research report on Monday, January 19th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $27.67.

Insiders Place Their Bets

In other Elanco Animal Health news, CEO Jeffrey N. Simmons bought 22,000 shares of Elanco Animal Health stock in a transaction on Thursday, December 11th. The shares were acquired at an average price of $21.75 per share, for a total transaction of $478,500.00. Following the completion of the purchase, the chief executive officer directly owned 167,000 shares in the company, valued at approximately $3,632,250. This trade represents a 15.17% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Robert M. Vanhimbergen bought 6,950 shares of the stock in a transaction dated Thursday, December 11th. The shares were bought at an average cost of $21.64 per share, with a total value of $150,398.00. Following the completion of the purchase, the chief financial officer directly owned 124,233 shares of the company’s stock, valued at approximately $2,688,402.12. This trade represents a 5.93% increase in their position. The SEC filing for this purchase provides additional information. In the last ninety days, insiders have acquired 43,450 shares of company stock worth $937,883. 0.89% of the stock is currently owned by company insiders.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.